Table 2.
Pathologic findings in patients < 65 years and > 65 years.
| Pathologic finding | < 65 years | > 65 years | P value |
|---|---|---|---|
| Histopathology | |||
| Infiltrating ductal | 739 (70,5%) | 323 (72%) | NS |
| Infiltrating lobular | 79 (7,5%) | 54 (12%) | <0,01 |
| Ductal Carcinoma In Situ DCIS | 231 (22%) | 72 (16%) | <0,01 |
| Grading | |||
| G1 | 262 (25%) | 112 (25%) | NS |
| G2 | 451(43%) | 238 (53%) | <0,01 |
| G3 | 336 (32%) | 99 (22%) | <0,01 |
| Tumor size | |||
| Median | 1.2 | 1.2 | NS |
| 0-2 | 786 (75%) | 327 (73%) | NS |
| 2-5 | 199 (19%) | 103 (23%) | NS |
| >5 | 64 (6%) | 19 (4%) | NS |
| Node positive | 245/818 (30%) | 102/377 (27%) | NS |
| Involved nodes | |||
| Mean | 3.9 | 3.7 | NS |
| 0 | 573 (70%) | 275 (73%) | NS |
| 1-3 | 155 (19%) | 64 (17%) | NS |
| >4 | 90 (11%) | 38 (10%) | NS |
| Estrogen receptor positive | 797 (76%) | 386 (86%) | <0,01 |
| Axillary node surgery | 793 (97%) | 301 (80%) | <0,01 |
| Surgery | |||
| Breast Conservation | 776 (74%) | 125 (28%) | <0,001 |
| Mastectomy | 273 (26%) | 324 (72%) | <0,001 |
| Neoadjuvant chemotherapy | 189 (18%) | 13 (3%) | <0,001 |
| Postoperative chemotherapy | 367 (35%) | 36 (8%) | <0,001 |
| Tamoxifen/Aromatase inhibitor | 598/797 (75%) | 301/386 (78%) | NS |
| Radiation therapy after BCS | 753/776 (97%) | 66/125 (53%) | <0,001 |